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Abstract 
Background 
Adaptive designs are somewhat underused, despite prominence given to methodology 
in the statistical literature. Some concerns relates to robustness of adaptive designs in 
decision making, acceptability of trial findings to change practice, anxiety about early 
stopping of trials and worry about wrong decision making. These issues could be linked to 
inadequate reporting of the conduct of such clinical trials. We assess the reporting of group 
sequential randomised controlled trials (RCTs), which are one of the most well-understood 
adaptive designs in the confirmatory setting. 
Methods 
We undertake a systematic review searching Ovid MEDLINE from 1st January 2001 
to 23rd September 2014 and including parallel group confirmatory group sequential RCTs that 
were prospectively designed using the Frequentist approach. Eligible trials are screened for 
completeness in reporting against the CONSORT 2010 checklist with some proposed 
modifications to capture issues such as statistical bias correction following early stopping. 
Descriptive statistics aided with forest plots on CONSORT compliance are presented. 
Discussion 
Reporting of the conduct of adaptive designs is an area which has not been fully 
explored. Hence, the findings from this study can enlighten us on the adequacy in reporting 
of well-understood group sequential RCTs as a class of adaptive designs and on ways to 
address some of the cited concerns. Most importantly, the study can inform policy makers on 
the adequacy of the current CONSORT statements in enhancing reporting of such adaptive 
designs. 
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Introduction 
The CONSORT Statement is a guidance to facilitate reporting of randomized 
controlled trials (RCTs), first introduced in 1996 [1] and later revised in 2001 and 2010 [2, 
3]. There has been a marked improvement in the reporting of RCTs following the publication 
of the initial CONSORT statement and a checklist exists, which is tailored for superiority 
parallel group, fixed sample size design randomised controlled trials (RCTs) [4, 5]. Since 
then, extensions have been made to accommodate other trials designs and hypotheses such as 
Cluster RCTs, non-inferiority and equivalence trials, and pragmatic RCTs [6±9]. However, 
there are still general deficiencies in reporting of RCTs [10]. As of the 23rd September 2014, 
at least 30 reporting guidance documents are being developed to enhance transparency in 
reporting [7]. 
Recently, adaptive designs where planned modifications to some aspects of the trial 
are permissible, based on accumulating information from that ongoing trial, have been 
receiving some attention. There are indications that the uptake of adaptive designs is now 
gaining some traction [11, 12] and there have been various cross industry initiatives including 
regulators to facilitate and foster discussions, obtain some form of consensus and address 
issues associated with their use [13±19]. As a result of these initiatives, cautiously expect the 
uptake of adaptive designs to improve in the future due to these initiatives. However, one of 
the most common concerns raised by regulators and the research community associated with 
the use of adaptive designs , especially in confirmatory trials, is the potential to introduce bias 
and compromise the credibility, integrity and validity of the trial findings during trial 
conduct, due to the dissemination of interim results [18, 20, 22].  
An important way to obviate such worry about potential bias is through transparency 
and adequate reporting by trialists, for consumers of research findings to make informed 
judgements regarding the quality of the research in front of them. Results from recent 
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qualitative interviews of key stakeholders in clinical trials research found that some 
researchers were concerned about methodological rigour and robustness, and also questioned 
whether the current reporting guidance framework is adequate enough for clinicians and 
policy makers to make informed judgements [23].  In addition, these interviews suggested 
that transparency in conduct and reporting is key to the acceptability of the findings from an 
adaptive RCT, especially in the confirmatory phase. Some recommendations for CONSORT 
modifications have been suggested elsewhere although they did not look at the current state 
of affairs in reporting of adaptive designs [19, 24].  Bearing this in mind, we undertake a 
review of peer reviewed and published journal reports to investigate the completeness of 
reporting of GS (group sequential) RCTs. A GS RCT, which is a class of adaptive designs, 
has been in use for a number of years in the confirmatory setting. It is described by regulators 
as well-understood and has promising future prospects [20±22]. We believe the findings will 
enlighten and inform policy on whether the reporting of GS RCTs is adequate enough within 
the scope of the current CONSORT guidance, as well as informing the need for a modified 
CONSORT guidance to accommodate adaptive designs. 
Objectives 
The purpose of this study is to investigate the adequacy in reporting of GS RCTs in 
order for consumers of research to make informed judgements about the quality of the 
research. The specific objectives are to; 
 Investigate completeness in reporting within the scope of the current CONSORT 
guidance checklist 
 Investigate the shortcomings of the current CONSORT guidance in enhancing the 
reporting of GS RCTs, that is, what sort of missing relevant information should be 
reported 
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 Provide recommendations for policy makers regarding adequate reporting of adaptive 
designs 
 3URYLGHDFROOHFWLRQRIFDVHVWXGLHVRI*65&7VSXEOLVKHGLQ³KLJKLPSDFW´SHHU
reviewed medical journals 
Methods 
Review approach and search strategy 
We undertake a systematic review of published peer reviewed GS RCT reports 
indexed in Ovid MEDLINE. We chose to conduct the searches through Ovid due to the 
efficiency of the searches compared to those done through PubMed or Web of Science. We 
aim to maximise the number of relevant trials in our search results, whilst minimising the 
number of irrelevant trial reports. One of the main challenges of methodological systematic 
review of this nature is the lack of consistent and efficient MeSH terms to base the searches 
RQ)RULQVWDQFHRXUVFRSLQJH[HUFLVHIRXQGRQO\RQHUHOHYDQW0H6+WHUP³(DUO\
7HUPLQDWLRQLQ&OLQLFDO7ULDOV´DVVRFLDWHGZLWK*6PHWKRGRORJ\WKURXJK3XE0HG7KLV
proved to be inefficient through Ovid, since no records were retrieved. In addition, it only 
retrieved 292 reports through PubMed which we believe is insensitive. We therefore employ 
keywords associated with GS methodology (Table 1) which are often used by 
statisticians/trialists during communication and dissemination together with filters, as 
discussed in Section on screening for eligibility. 
Table 1: Search strategy using keywords 
Search Exact search terms Filters 
1 Group sequential  Check tags  
o Humans 
o Full text available 
o English language  
2 Interim analysis 
Interim analyses 
3 Stopping rule 
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Stopping rules 
Stopping boundaries 
Stopping boundary  
 Publication types 
o Clinical trials; phase III 
 Period (01/01/2001 to 23/09/2014) 
4 Interim monitoring 
5 Early stopping 
6 Early termination 
7 Accumulating data 
8 Accumulating information 
 
7KHILQDOVHDUFKFDQEHFRPELQHGXVLQJD%RROHDQRSHUDWRU³25´DVIROORZVOR 2 OR 3 
OR 4 OR 5 OR 6 OR 7 OR 8). 
In addition, we supplement the search by using reports of known GS RCTs retrieved from 
another ongoing study. 
Screening for eligibility 
We employ the following inclusion and exclusion criteria to filter relevant or eligible reports; 
 Include RCTs with two or more arms 
 Include only English Language reports  
o Exclude other languages for practicalities 
 Include trials with full text available otherwise it would be impossible to evaluate 
completeness in reporting 
o Exclude trials with abstract only 
 Include trials only conducted in humans 
o No restriction on the population (paediatric and adults ) 
 Include all trials regardless of the nature of the primary endpoint(s) 
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o No restriction on the nature of the primary outcome(s): continuous, binary, 
time to event, ordinal, categorical and count  
 Study design characteristics 
o Randomised controlled trials 
 Exclude observational studies 
o Prospectively planned group sequential RCTs regardless of the reason to stop 
early 
o Parallel group  
 Exclude crossover and cluster randomised trials due to the fact that 
these designs have certain additional specific reporting requirements 
 Include only phase III or confirmatory trials 
o Exclude phase I or II or II/III or IV  
 Time period takes into account the publication history of the CONSORT statement 
but excludes the first period to allow for publicity to the wider research community. 
The checklist items of the latest 2010 version are used to measure quality in reporting 
o First version to be excluded was published in 1995  and become effective in 
1996)  [1]  
o Second version published in 2001 [2]  
o Third latest version published in March 2010 [3]  
o Therefore, we include reports between 01/01/2001 to 29/09/2014     
Data extraction and management  
Citation information of retrieved reports, such as title, authors, journal details and 
publication year, together with the abstract, are exported to Excel or Reference Manager or 
Endnote software, depending on the preferences of the reviewers. Duplicate records are 
checked with respect to first author, title and publication year. Retrieved duplicate records are 
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manually cross checked before deletion. Data extraction sheet can then be used for further 
filtering of relevant papers. A further data extraction is then used to extract study 
characteristics of interests in order to answer the research question. Two reviewers 
independently extract study characteristics of interests and assess the quality in reporting, in 
line with the modified CONSORT checklist. Cross validation of the extracted material is 
done between two independent reviewers. 
Study primary outcome  
Our primary outcome is compliance to the CONSORT 2010 checklist items which is 
subjectively measured by two independent assessors according to an initially agreed 
FODVVLILFDWLRQV\VWHP³DEVHQW´³SDUWLDOO\FRPSOHWH´³WRWDOO\FRPSOHWH´³FDQQRWDVVHVV´DQG
³QRWDSSOLFDEOH´)XUWKHUDVVXPSWLRQVFDQEHPDGHWRFUHDWH a binary outcome to assess 
CONSORT compliance using logistic regression.  
Analysis and Reporting   
Statistical analysis is mainly descriptive in nature and reporting in accordance with 
the PRISMA checklist [25, 26], includes, a flowchart describing identification of records 
from all different sources, screening and eligibility, and a summary of study characteristics of 
included eligible studies depending on the nature of the variables of interest. For instance, 
numbers and proportions for binary or categorical variables and numbers, mean (SD) or 
median (IQR) for continuous variables depending on their underlying distributions.  Numbers 
and proportions are used to summarise trials meeting completeness in reporting of certain 
dimensions of the CONSORT checklist and other research driven dimensions. In addition, 
completeness in reporting is considered by variable of interest such as funder (private or 
public), intervention type (drug and non-drug), whether the journal endorse the CONSORT 
statement (endorsers and non-endorsers [27]) and publication period (before and after 2010 
CONSORT revision). Difference in completeness for each CONSORT checklist item 
10 
 
stratified by factor variable is presented as Odds Ratios (ORs) with associated 95% CI using 
logistic regression. Furthermore, we utilise clustered histograms and forest plots to aid 
presentation of the findings. 
Discussion  
Previous literature suggested that there are general deficiencies in the reporting of 
RCTs [10]. The use of CONSORT statements has seen a marked improvement in 
completeness of reporting of RCTs in general, although it remains sub-optimal [28]. 
Although much research has been undertaken investigating general adherence to the 
CONSORT checklists in RCTs [28, 29], we are not aware of similar research investigating 
adequacy in reporting in the class of adaptive designs such as GS RCTs. The need for our 
study has been informed by a prior nested qualitative study which found fear of making 
wrong decisions and concerns about the robustness of adaptive designs in confirmatory 
decision making as some of the barriers to their uptake. In addition, varying level of practical 
and statistical complexity associated with adaptive designs increases the risk of the potential 
introduction of bias in the conduct of the studies and thereby compromising the integrity, 
credibility and validity of the finding. We postulate that the concerns about wrong decision 
making could be related to transparency in conduct and reporting. For instance, lack of detail 
regarding a key aspect of an adaptive trial is likely to lead to reluctance to accept the findings 
by the research community.  
What does this study add? 
Although some suggestions to modify the CONSORT guidance for adaptive designs 
have been proposed elsewhere [19, 24]; to the best of our knowledge, we are not aware of 
previous studies investigating the current state of affairs in adaptive designs in line with the 
current CONSORT guidance. Therefore, the findings from this study enlighten us on the 
adequacy in reporting of GS RCTs as a class of adaptive designs. Most importantly, it 
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informs policy makers on the adequacy of the current CONSORT statements in enhancing 
reporting of adaptive designs. Thus, it highlights whether there is scope for a modified 
CONSORT statement for adaptive designs; and if so, what additional information should be 
reported and whether previous suggested modifications are adequate.  
Strength and limitations  
The main strength of this study is that it is filling the gap based on adaptive designs 
related concerns raised by the research community and regulators identified during an 
ongoing study investigating the use of adaptive designs in the confirmatory setting [23]. One 
of the main methodological shortcomings due to resources and time limitation is restriction to 
the Ovid MEDLINE database. We acknowledge that there could be some GS RCT reports 
which may not be indexed in Ovid MEDLINE but other databases such as EMBASE and 
PubMed. In addition, the lack of consistent MeSH terms describing GS RCTs limited the 
efficiency of our searches. However, we have also supplemented the search strategy by 
searching reports of known and completed GS RCTs from another ongoing study. Despite the 
fact that our search strategy may not be exhaustive, we believe it is robust enough to answer 
the research question and inform us on the state of affairs of reporting of GS RCTs.  
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